Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

Trial Profile

Randomized Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Relapsed/Refractory Triple-Negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2017

At a glance

  • Drugs Sacituzumab govitecan (Primary) ; Carboplatin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Sponsors Immunomedics
  • Most Recent Events

    • 09 Feb 2017 According to an Immunomedics media release, updated results from the study were presented at the 2016 San Antonio Breast Cancer Symposium.
    • 18 Jan 2017 Interim results were published in the Immunomedics Media Release.
    • 09 Jan 2017 According to Immunomedics media release, results of this study will be published in a peer-reviewed medical journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top